Reduced Endothelium-Dependent Relaxation to Anandamide in Mesenteric Arteries from Young Obese Zucker Rats

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Lobato, Nubia S ^a,b,c   Filgueira, Fernando P ^a,b,c   Prakash, Roshini ^b   Giachini, Fernanda R ^b   Ergul, Adviye ^b   Carvalho, Maria Helena C ^c   Webb, R Clinton ^b   Tostes, Rita C ^c   Fortes, Zuleica B ^c  

^a FEDERAL UNIVERSITY OF GOIÁS   (Brazil)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; ACETYLCHOLINE; ANANDAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CYCLIC AMP DEPENDENT PROTEIN KINASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FATTY ACID AMIDASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; NITROPRUSSIDE SODIUM; VANILLOID RECEPTOR 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL REACTIVITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FAT MASS; IMMUNOFLUORESCENCE TEST; IN VITRO STUDY; MALE; MESENTERIC ARTERY; MOLECULAR DYNAMICS; MYOGRAPHY; NONHUMAN; OBESITY; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAT; SIGNAL TRANSDUCTION; VASCULAR RESISTANCE; VASODILATATION; WEIGHT GAIN; WESTERN BLOTTING;

ACETYL-COA CARBOXYLASE; ADENYLATE KINASE; ANIMALS; ARACHIDONIC ACIDS; CANNABINOID RECEPTOR AGONISTS; ENDOCANNABINOIDS; ENDOTHELIUM, VASCULAR; MALE; MESENTERIC ARTERIES; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; OBESITY; PHOSPHORYLATION; POLYUNSATURATED ALKAMIDES; PROTEIN TRANSPORT; RATS; RATS, ZUCKER; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; TRPV CATION CHANNELS; VASODILATION;

EID: 84877157642     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0063449     Document Type: Article

References (62)

1. Flegal KM, Carroll MD, Ogden CL, Johnson CL, (2002) Prevalence and trends in obesity among US adults, 1999-2000. JAMA 288 (14): 1723-1727.
2. Hill JO, (2006) Understanding and addressing the epidemic of obesity: an energy balance perspective. Endocr Rev 27 (7): 750-761.
3. Echahidi N, Mohty D, Pibarot P, Despres JP, O'Hara G, et al. (2007) Obesity and metabolic syndrome are independent risk factors for atrial fibrillation after coronary artery bypass graft surgery. Circulation 116 (11 Suppl): I213-219.
4. Stapleton PA, James ME, Goodwill AG, Frisbee JC, (2008) Obesity and vascular dysfunction. Pathophysiology 15 (2): 79-89.
5. Gokce N, Keaney JF, Hunter LM, Watkins MT, Nedeljkovic ZS, et al. (2003) Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events in patients with peripheral vascular disease. J Am Coll Cardiol 41 (10): 1769-1775.
6. Lerman A, Zeiher AM, (2005) Endothelial function: cardiac events. Circulation 111 (3): 363-368.
7. Mitchell GF, Parise H, Vita JA, Larson MG, Warne E, et al. (2004) Local shear stress and brachial artery flow-mediated dilation: the Framingham Heart Study. Hypertension 44 (2): 134-139.
8. Engeli S, Bohnke J, Feldpausch M, Gorzelniak K, Janke J, et al. (2005) Activation of the peripheral endocannabinoid system in human obesity. Diabetes 54 (10): 2838-2843.
9. Matias I, Petrosino S, Racioppi A, Capasso R, Izzo AA, et al. (2008) Dysregulation of peripheral endocannabinoid levels in hyperglycemia and obesity: Effect of high fat diets. Mol Cell Endocrinol 286 (1-2Suppl 1): S66-78.
10. Szmitko PE, Verma S, (2008) The endocannabinoid system and cardiometabolic risk. Atherosclerosis 199 (2): 248-256.
11. Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, et al. (1996) Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 384 (6604): 83-87.
12. Di Marzo V, (2008) Targeting the endocannabinoid system: to enhance or reduce? Nat Rev Drug Discov 7 (5): 438-455.
13. Liu J, Wang L, Harvey-White J, Huang BX, Kim HY, et al. (2008) Multiple pathways involved in the biosynthesis of anandamide. Neuropharmacology 54 (1): 1-7.
14. Mackie K, Stella N, (2006) Cannabinoid receptors and endocannabinoids: evidence for new players. AAPS J 8 (2): E298-306.
15. Cota D, Marsicano G, Tschop M, Grubler Y, Flachskamm C, et al. (2003) The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 112 (3): 423-431.
16. Gardiner SM, March JE, Kemp PA, Bennett T, (2009) Factors influencing the regional haemodynamic responses to methanandamide and anandamide in conscious rats. Br J Pharmacol 158 (4): 1143-1152.
17. Wheal AJ, Bennett T, Randall MD, Gardiner SM, (2007) Cardiovascular effects of cannabinoids in conscious spontaneously hypertensive rats. Br J Pharmacol 152 (5): 717-724.
18. Grainger J, Boachie-Ansah G, (2001) Anandamide-induced relaxation of sheep coronary arteries: the role of the vascular endothelium, arachidonic acid metabolites and potassium channels. Br J Pharmacol 134 (5): 1003-1012.
19. Herradon E, Martin MI, Lopez-Miranda V, (2007) Characterization of the vasorelaxant mechanisms of the endocannabinoid anandamide in rat aorta. Br J Pharmacol 152 (5): 699-708.
20. Lipez-Miranda V, Herradon E, Martin MI, (2008) Vasorelaxation caused by cannabinoids: mechanisms in different vascular beds. Curr Vasc Pharmacol 6 (4): 335-346.
21. Deutsch DG, Goligorsky MS, Schmid PC, Krebsbach RJ, Schmid HH, et al. (1997) Production and physiological actions of anandamide in the vasculature of the rat kidney. J Clin Invest 100 (6): 1538-1546.
22. Wagner JA, Varga K, Járai Z, Kunos G, (1999) Mesenteric vasodilation mediated by endothelial anandamide receptors. Hypertension 33 (1 Pt 2): 429-34.
23. Hillard CJ, (2000) Endocannabinoids and vascular function. J Pharmacol Exp Ther 294 (1): 27-32.
24. Randall MD, Kendall DA, O'Sullivan S, (2004) The complexities of the cardiovascular actions of cannabinoids. Br J Pharmacol 142 (1): 20-26.
25. Pratt PF, Hillard CJ, Edgemond WS, Campbell WB, (1998) N-arachidonylethanolamide relaxation of bovine coronary artery is not mediated by CB1 cannabinoid receptor. Am J Physiol 274 (1 Pt 2): H375-81.
26. Mulvany MJ, Halpern W, (1977) Contractile properties of small arterial resistance vessels in spontaneously hypertensive and normotensive rats. Circ Res 41 (1): 19-26.
27. O'Sullivan SE, Kendall DA, Randall MD, (2004) Heterogeneity in the mechanisms of vasorelaxation to anandamide in resistance and conduit rat mesenteric arteries. Br J Pharmacol 142 (3): 435-442.
28. Jiang S, Fu Y, Williams J, Wood J, Pandarinathan L, et al. (2007) Expression and function of cannabinoid receptors CB1 and CB2 and their cognate cannabinoid ligands in murine embryonic stem cells. PLoS One 2 (7): e641.
29. Kaczocha M, Glaser ST, Deutsch DG, (2009) Identification of intracellular carriers for the endocannabinoid anandamide. Proc Natl Acad Sci USA 106 (15): 6375-6380.
30. Goirand F, Solar M, Athea Y, Viollet B, Mateo P, et al. (2007) Activation of AMP kinase alpha1 subunit induces aortic vasorelaxation in mice. J Physiol 581 (Pt 3): 1163-1171.
31. Lobato NS, Filgueira FP, Akamine EH, Davel AP, Rossoni LV, et al. (2011) Obesity induced by neonatal treatment with monosodium glutamate impairs microvascular reactivity in adult rats: role of NO and prostanoids. Nutr Metab Cardiovasc Dis 21 (10): 808-16.
32. Holzer P, (1991) Capsaicin: cellular targets, mechanisms of action, and selectivity for thin sensory neurons. Pharmacol Rev 43 (2): 143-201.
33. Scotland RS, Chauhan S, Davis C, De Felipe C, Hunt S, et al. (2004) Vanilloid receptor TRPV1, sensory C-fibers, and vascular autoregulation: a novel mechanism involved in myogenic constriction. Circ Res 95 (10): 1027-1034.
34. Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, et al. (1997) The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 389 (6653): 816-824.
35. Bevan S, Hothi S, Hughes G, James IF, Rang HP, et al. (1992) Capsazepine: a competitive antagonist of the sensory neurone excitant capsaicin. Br J Pharmacol 107 (2): 544-552.
36. Dray A, Forbes CA, Burgess GM, (1990) Ruthenium red blocks the capsaicin-induced increase in intracellular calcium and activation of membrane currents in sensory neurones as well as the activation of peripheral nociceptors in vitro. Neurosci Lett 110 (1-2): 52-59.
37. Zygmunt PM, Andersson DA, Hogestatt ED, (2002) Delta 9-tetrahydrocannabinol and cannabinol activate capsaicin-sensitive sensory nerves via a CB1 and CB2 cannabinoid receptor-independent mechanism. J Neurosci 22 (11): 4720-4727.
38. Rayment SJ, Ralevic V, Barrett DA, Cordell R, Alexander SP, (2007) A novel mechanism of vasoregulation: ADP-induced relaxation of the porcine isolated coronary artery is mediated via adenosine release. FASEB J 21 (2): 577-585.
39. Ralevic V, Kendall DA, Randall MD, Zygmunt PM, Movahed P, et al. (2000) Vanilloid receptors on capsaicin-sensitive sensory nerves mediate relaxation to methanandamide in the rat isolated mesenteric arterial bed and small mesenteric arteries. Br J Pharmacol 130: 1483-1488.
40. Wagner JA, Varga K, Ellis EF, Rzigalinski BA, Martin BR, et al. (1997) Activation of peripheral CB1 cannabinoid receptors in haemorrhagic shock. Nature 390(6659): 518-21.
41. Varga K, Wagner JA, Bridgen DT, Kunos G, (1998) Platelet- and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension. FASEB J. 12(11): 1035-44.
42. Kadoi Y, Hinohara H, Kunimoto F, Saito S, Goto F, (2005) Cannabinoid antagonist AM 281 reduces mortality rate and neurologic dysfunction after cecal ligation and puncture in rats. Crit Care Med. 33(11): 2629-2636.
43. Wagner JA, Hu K, Bauersachs J, Karcher J, Wiesler M, et al. (2001) Endogenous cannabinoids mediate hypotension after experimental myocardial infarction. J Am Coll Cardiol. 38(7): 2048-2054.
44. Gaskari SA, Liu H, Moezi L, Li Y, Baik SK, et al. (2005) Role of endocannabinoids in the pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated rats. Br J Pharmacol. 146(3): 315-23.
45. Mukhopadhyay P, Bátkai S, Rajesh M, Czifra N, Harvey-White J, et al. (2007) Pharmacological inhibition of CB1 cannabinoid receptor protects against doxorubicin-induced cardiotoxicity. J Am Coll Cardiol. 50(6): 528-536.
46. Bátkai S, Pacher P, Osei-Hyiaman D, Radaeva S, Liu J, et al. (2004) Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension. Circulation. 110(14): 1996-2002.
47. Sarzani R, (2008) Endocannabinoids, blood pressure and the human heart. J Neuroendocrinol. 20(1): 58-62.
48. Zucker LM, Antoniades HN, (1972) Insulin and obesity in the Zucker genetically obese rat "fatty". Endocrinology 90 (5): 1320-1330.
49. Stepp DW, Boesen EI, Sullivan JC, Mintz JD, Hair CD, et al. (2007) Obesity augments vasoconstrictor reactivity to angiotensin II in the renal circulation of the Zucker rat. Am J Physiol Heart Circ Physiol 293 (4): H2537-H2542.
50. Subramanian R, MacLeod KM, (2003) Age-dependent changes in blood pressure and arterial reactivity in obese Zucker rats. Eur J Pharmacol 477 (2): 143-152.
51. Kotsis V, Stabouli S, Papakatsika S, Rizos Z, Parati G, (2010) Mechanisms of obesity-induced hypertension. Hypertens Res. 33(5): 386-393.
52. Blüher M, Engeli S, Klöting N, Berndt J, Fasshauer M, et al. (2006) Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes. 55(11): 3053-60.
53. Côté M, Matias I, Lemieux I, Petrosino S, Alméras N, et al. (2007) Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men. Int J Obes 31(4): 692-699.
54. Randall MD, Kendall DA, O'Sullivan S, (2004) The complexities of the cardiovascular actions of cannabinoids. Br J Pharmacol 142 (1): 20-26.
55. Shaul PW, (2002) Regulation of endothelial nitric oxide synthase: location, location, location. Annu Rev Physiol 64: 749-774.
56. Chen Z, Peng IC, Sun W, Su MI, Hsu PH, et al. (2009) AMP-activated protein kinase functionally phosphorylates endothelial nitric oxide synthase Ser633. Circ Res 104 (4): 496-505.
57. Kola B, Hubina E, Tucci SA, Kirkham TC, Garcia EA, et al. (2005) Cannabinoids and ghrelin have both central and peripheral metabolic and cardiac effects via AMP-activated protein kinase. J Biol Chem 280 (26): 25196-25201.
58. Chen ZP, Mitchelhill KI, Michell BJ, Stapleton D, Rodriguez-Crespo I, et al. (1999) AMP-activated protein kinase phosphorylation of endothelial NO synthase. FEBS Lett 443 (3): 285-289.
59. Moncada S, Rees DD, Schulz R, Palmer RM, (1991) Development and mechanism of a specific supersensitivity to nitrovasodilators after inhibition of vascular nitric oxide synthesis in vivo. Proc Natl Acad Sci U S A 88 (6): 2166-2170.
60. Zygmunt PM, Petersson J, Andersson DA, Chuang H, Sorgard M, et al. (1999) Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 400 (6743): 452-457.
61. Kawasaki H, Takasaki K, Saito A, Goto K, (1988) Calcitonin gene-related peptide acts as a novel vasodilator neurotransmitter in mesenteric resistance vessels of the rat. Nature 335 (6186): 164-167.
62. Gunthorpe MJ, Benham CD, Randall A, Davis JB, (2002) The diversity in the vanilloid (TRPV) receptor family of ion channels. Trends Pharmacol Sci 23 (4): 183-191.